Clinical Trial Update: Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

View source ↗

Summary

This document reports a long-term follow-up registry study of Equecabtagene Autoleucel for multiple myeloma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Equecabtagene Autoleucel Injection (equecabtagene autoleucel)

Snippet

Sponsor: Nanjing IASO Biotechnology Co., Ltd. | Conditions: Multiple Myeloma | Status: RECRUITING